149 Views
Sunday Poster Session
Category: Biliary/Pancreas
Anas Chennouf, MD
CIUSSS de l'Estrie-CHUS
Sherbrooke, QC, Canada
| Plastic stents group (N=29) | Metal stent group (N=15) |
|
Outcome | N (%) | N (%) | P-value |
Re-intervention for stent dysfunction | 8 (27,5%) | 0 (0%) | P = 0,037 |
PBD-related adverse events
| 9 (31%) | 1 (6,7%) | P = 0,08 |
Pancreatitis | 0 (0%) | 1 (6,7%) |
|
Cholangitis | 5 (17,2%) | 0 (0%) | |
Stent obstruction without cholangitis | 3 (10,3%) | 0 (0%) | |
Hemorrhagic shock due to spleen laceration | 1 (3,4%) | 0 (0%) | |
Interval to surgery after PBD (days) median [25-75e percentile] | 34 [23-48] | 36 [19-50] | P = 0,862 |
Pre-ERCP total bilirubine value (μmol/L) median [25-75e percentile] | 162 [113-379] | 227 [168-384] | P = 0,480 |
Peri-operative total bilirubine value (μmol/L) median [25-75e percentile] | n=23 23 [12-31] | 26 [18-40] | P = 0,591 |
Time to 50% bilirubine reduction after PBD (days) median [25-75e percentile] | n=25 11 [5-23] | 19 [8-25] | P = 0,349 |
Total bilirubine normalization before surgery | 6/26 (21%) | 3 (20%) | P = 1 |
Time to total bilirubine normalization after-PBD (days) Mean ± SD | n=6 35,8 ± 25,9 | n=3 48,7 ± 12,1 | P = 0,302 |